share_log

開拓藥業-B：截至2024年6月30日止六個月之中期業績公告

KINTOR PHARMA-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024

HKEX ·  Aug 26, 2024 20:55

Summary by Moomoo AI

開拓藥業-B宣佈截至2024年6月30日止六個月的未經審核中期業績，與去年同期相比，虧損淨額由人民幣212.1百萬元減少至人民幣71.5百萬元，減少66.3%。該減少主要由於研發成本及行政開支的減少。研發成本由人民幣164.6百萬元減少至人民幣39.3百萬元，減少76.1%，主要因為集團更加聚焦核心皮科管線投入，而腫瘤管線投入大幅減少。行政開支由人民幣51.2百萬元減少至人民幣33.9百萬元，減少33.8%，主要是因為員工福利及以股份為基礎的薪酬開支減少。本集團現金及現金等價物以及定期存款為人民幣333.7百萬元，並有未動用的銀行融資人民幣80.0百萬元，資金充裕。董事會決議不派付任何中期股息...展開全部
開拓藥業-B宣佈截至2024年6月30日止六個月的未經審核中期業績，與去年同期相比，虧損淨額由人民幣212.1百萬元減少至人民幣71.5百萬元，減少66.3%。該減少主要由於研發成本及行政開支的減少。研發成本由人民幣164.6百萬元減少至人民幣39.3百萬元，減少76.1%，主要因為集團更加聚焦核心皮科管線投入，而腫瘤管線投入大幅減少。行政開支由人民幣51.2百萬元減少至人民幣33.9百萬元，減少33.8%，主要是因為員工福利及以股份為基礎的薪酬開支減少。本集團現金及現金等價物以及定期存款為人民幣333.7百萬元，並有未動用的銀行融資人民幣80.0百萬元，資金充裕。董事會決議不派付任何中期股息。業務方面，本集團擁有6款處於I-III期臨床階段的潛在同類首創╱同類最佳的在研藥物，並在全球快速推進各項臨床試驗。其中，KX-826與米諾地爾聯合治療成年男性脫髮的Ib/III期臨床試驗已獲國家藥監局批准，GT20029治療脫髮的中國II期臨床試驗達到主要終點，且安全性和耐受性良好。本集團正式推出針對脫髮的外用防脫液，是全新高端化妝品品牌KOSHINÉ的首款產品。
Kaituo Pharmaceuticals-B announced its unaudited interim performance for the six months ended June 30, 2024. Compared with the same period last year, the net loss decreased from 212.1 million RMB to 71.5 million RMB, a decrease of 66.3%. The decrease was mainly due to the reduction in research and development costs and administrative expenses. Research and development costs decreased from 164.6 million RMB to 39.3 million RMB, a decrease of 76.1%, mainly due to the group's increased focus on core dermatology pipeline investment, while the investment in oncology pipeline decreased significantly. Administrative expenses decreased from 51.2 million RMB to 33.9 million RMB, a decrease of 33.8%, mainly due to the reduction in employee benefits and equity-based compensation expenses. The group's cash and cash equivalents, as well as...Show More
Kaituo Pharmaceuticals-B announced its unaudited interim performance for the six months ended June 30, 2024. Compared with the same period last year, the net loss decreased from 212.1 million RMB to 71.5 million RMB, a decrease of 66.3%. The decrease was mainly due to the reduction in research and development costs and administrative expenses. Research and development costs decreased from 164.6 million RMB to 39.3 million RMB, a decrease of 76.1%, mainly due to the group's increased focus on core dermatology pipeline investment, while the investment in oncology pipeline decreased significantly. Administrative expenses decreased from 51.2 million RMB to 33.9 million RMB, a decrease of 33.8%, mainly due to the reduction in employee benefits and equity-based compensation expenses. The group's cash and cash equivalents, as well as time deposits, amounted to 333.7 million RMB, and there was unused bank financing of 80.0 million RMB, indicating sufficient funds. The board of directors decided not to distribute any interim dividends. In terms of business, the group has 6 potential first-in-class/best-in-class investigational drugs in Phase I-III clinical stages, with various clinical trials progressing rapidly worldwide. Among them, the Ib/III clinical trial of KX-826 in combination with minoxidil for the treatment of male pattern hair loss has been approved by the National Medical Products Administration. The Phase II clinical trial of GT20029 for the treatment of hair loss in China has achieved the primary endpoint and demonstrated good safety and tolerability. The group has officially launched a topical anti-hair loss solution targeting hair loss, which is the first product of the new high-end cosmetic brand KOSHINÉ.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated